Market cap
$157 Mln
Recently Viewed
Clear AllMarket cap
$157 Mln
Revenue (TTM)
$21 Mln
P/E Ratio
--
P/B Ratio
2.1
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-45 Mln
ROE
-0.6 %
ROCE
-- %
Industry P/E
--
EV/EBITDA
-2.3
Debt to Equity
0.1
Book Value
$--
EPS
$-2
Face value
--
Shares outstanding
21,981,900
CFO
$-39.68 Mln
EBITDA
$-77.55 Mln
Net Profit
$-79.92 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
FStar Therapeutics Inc (FSTX)
| 12.7 | 44.7 | 34.8 | 138.9 | 30.5 | -34.9 | -- |
|
BSE Sensex*
| -8.7 | 2.7 | -5.2 | -2.4 | 8.6 | 9.8 | 11.5 |
|
Company
|
2022
|
2021
|
2020
|
2019
|
2018
|
2017
|
|---|---|---|---|---|---|---|
|
FStar Therapeutics Inc (FSTX)
| 25.9 | -49.1 | 56.2 | -84.8 | -22.6 | 68.2 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
|
BSE Sensex
| 4.4 | 22.0 | 15.8 | 14.4 | 5.9 | 27.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
FStar Therapeutics Inc (FSTX)
|
7.1 | 156.5 | 21.2 | -44.8 | -209.2 | -61.7 | -- | 2.1 |
| 3.9 | 391.3 | 73.2 | -67.8 | -82.1 | -65.5 | -- | 5.2 | |
| 19.8 | 1,171.8 | 0.0 | -147.4 | -29,734.7 | -150.3 | -- | 6.8 | |
| 13.9 | 2,407.3 | 550.0 | 458.1 | -3.3 | 45.9 | 5.3 | 1.9 | |
| 5.2 | 1,069.4 | 4.5 | -340.2 | -518.6 | 501.4 | -- | 2.1 | |
| 15.5 | 2,005.2 | 17.2 | -102.1 | -363.1 | -19 | -- | 3.5 | |
| 16.7 | 1,178.0 | 403.3 | 22.8 | 3,081.6 | 9.1 | 417 | 4.3 | |
| 3.7 | 668.3 | 4.6 | -201.1 | -4,342.4 | -146.8 | -- | 5.5 | |
| 17.0 | 412.6 | 4.8 | 53.5 | -- | 12.2 | 10 | 1.1 | |
| 22.8 | 2,571.6 | 460.2 | -175.5 | -37.7 | -22.6 | -- | 3.6 |
F-star Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops tetravalent bispecific antibodies for cancer therapy. Its medicines are used in immuno-oncology treatments. The company's principal product candidate is FS118 and is... being evaluated in a proof-of-concept Phase 2 trial in PD-1/PD-L1 acquired resistance head and neck cancer patients. It is also developing first-in-human clinical study of FS222, a bispecific antibody that is in Phase 1 clinical trial targeting the costimulatory CD137 receptor and the inhibitory PD-L1 ligand. In addition, the company is also evaluating FS120 and SB 11285 for patients with advanced cancers, which are under Phase 1 clinical trials. F-star Therapeutics, Inc. was incorporated in 2002 and is headquartered in Cambridge, the United Kingdom. As of March 8, 2023, F-star Therapeutics, Inc. operates as a subsidiary of invoX Pharma Limited. Read more
Pres, CEO & Director
Dr. Eliot Richard Forster M.B.A., Ph.D.
Pres, CEO & Director
Dr. Eliot Richard Forster M.B.A., Ph.D.
Headquarters
Cambridge
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of FStar Therapeutics Inc (FSTX) is $7.12 (NASDAQ) as of 17-Mar-2023 09:30 EDT. FStar Therapeutics Inc (FSTX) has given a return of 30.54% in the last 3 years.
Since, TTM earnings of FStar Therapeutics Inc (FSTX) is negative, P/E ratio is not available.
The P/B ratio of FStar Therapeutics Inc (FSTX) is 2.13 times as on 17-Mar-2023, a 59 discount to its peers’ median range of 5.16 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2021
|
-2.73
|
0.88
|
|
2020
|
-1.16
|
0.69
|
|
2019
|
--
|
--
|
|
2018
|
--
|
--
|
|
2017
|
--
|
--
|
The 52-week high and low of FStar Therapeutics Inc (FSTX) are Rs -- and Rs -- as of 27-Apr-2026.
FStar Therapeutics Inc (FSTX) has a market capitalisation of $ 157 Mln as on 17-Mar-2023. As per SEBI classification, it is a company.
Before investing in FStar Therapeutics Inc (FSTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.